The clinical efficacy of CTSS inhibitors is currently under investigation in inflammatory disorders including RA, SLE, plaque psoriasis, and, more recently, SS, both in animal disease models25–27 and in human clinical trials28,29. This evidence concerns the gene CTSS and glycogen storage disease VI.